You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

Silva, Joãoa,b,c; Silva, Carlos Martinsa,b,c; Cruz, Franciscoa,b,c

Current Opinion in Urology:
doi: 10.1097/MOU.0000000000000007
BENIGN PROSTATIC HYPERPLASIA: Edited by Oliver Reich
Abstract

Purpose of review: The pharmacological treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) is based on alpha-blockers and 5α-reductase inhibitors isolated or in combination. Silodosin, an alpha-1A specific alpha-blocker is the only innovation in these groups of agents. This classical paradigm is being challenged by antimuscarinics, 5-phosphodiesterase inhibitors (PDE5i) and β3-adrenoreceptor agonists.

Recent findings: Silodosin is effective in reducing BPH/LUTS, including nocturia and shows little cardiovascular adverse events. Antimuscarinic drugs isolated or in combination with alpha-blockers improve storage symptoms without any harmful effect to the voiding function. PDE5i alone improve BPH/LUTS. Combination of PDE5i with alpha-blockers provides better symptomatic control than alpha-blockers alone. A recent head-to-head comparison of tadalafil 5 mg/day with tamsulosin 0.4 mg/day showed that these agents provided the same improvement in BPH/LUTS and, surprisingly, the same improvement in the urinary flow. In fact, previous studies with tadalafil had not shown any effect of tadalafil on flow. In addition, tadalafil but not tamsulosin improved sexual function. Mirabegron, the first β3-adrenoreceptor agonist, while improving BPH/LUTS in men with bladder outlet obstruction, do not decrease urinary flow or detrusor pressure.

Summary: The standard medical treatment for BPH/LUTS is still based on alpha-blockers, 5ARIs or its combination. In the future, it is expected that BPH/LUTS treatment will become individualized, according to the type of symptoms, presence of sexual dysfunction and risk of BPH progression. This will challenge our concept of standard treatment for BPH/LUTS.

Author Information

aDepartement of Urology, Hospital S. João

bFaculty of Medicine

cIBMC, Institute for Molecular and Cell Biology, Porto, Portugal

Correspondence to Professor Dr Francisco Cruz, Urology Department, Hospital de S. João, E.P.E., Alameda Professor Hernâni Monteiro, Porto 4200-319, Portugal. Tel: +351 225513654; fax: +351 225513655; e-mail: cruzfjmr@med.up.pt

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins